The DOI matches its Crossref record.
Increased Protein Oxidation in Human Substantia Nigra Pars Compacta in Comparison with Basal Ganglia and Prefrontal Cortex Measured with an Improved Dinitrophenylhydrazine Assay
Open accessAbstract
Abstract: The dopaminergic phenotype of neurons in human substantia nigra deteriorates during normal aging, and loss of these neurons is prominent in Parkinson's disease. These degenerative processes are hypothesized to involve oxidative stress. To compare oxidative stress in the nigra and related regions, we measured carbonyl modifications of soluble proteins in postmortem samples of substantia nigra, basal ganglia, and prefrontal cortex from neurologically normal subjects, using an improved 2,4‐dinitrophenylhydrazine assay. The protein carbonyl content was found to be about twofold higher in substantia nigra pars compacta than in the other regions. To further analyze this oxidative damage, the distribution of carbonyl groups on soluble proteins was determined by western immunoblot analysis. This method revealed that carbonyl content of the major proteins in each region was linearly dependent on molecular weight. This distribution raises the possibility that protein carbonyl content is controlled by a size‐dependent mechanism in vivo. Our results suggest that oxidative stress is elevated in human substantia nigra pars compacta in comparison with other regions and that oxidative damage is higher within the dopaminergic neurons. Elevated oxidative damage may contribute to the degeneration of nigral dopaminergic neurons in aging and in Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Free Radicals: Properties, Sources, Targets, and Their Implication in Various Diseases
Phaniendra, A., Jestadi, D. B., & Periyasamy, L. (2015) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-014-0446-0 · Cited by 2,886
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
The Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
Protein carbonylation in human diseases
Dalle-Donne, I., Giustarini, D., Colombo, R., Rossi, R., & Milzani, A. (2003) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(03)00031-5 · Cited by 961
Altered proteasomal function in sporadic Parkinson’s disease
St. P. McNaught, K., Belizaire, R., Isacson, O., Jenner, P., & Olanow, C. W. (2003) · Experimental Neurology · doi:10.1006/exnr.2002.8050 · Cited by 573
Manoharan, S., Guillemin, G. J., Abiramasundari, R. S., Essa, M. M., Akbar, M., & Akbar, M. D. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/8590578 · Cited by 523
Mitter, S. K., Song, C., Qi, X., Mao, H., Rao, H., Akin, D., Lewin, A., Grant, M., Dunn, W., Ding, J., et al. (2014) · Autophagy · doi:10.4161/auto.36184 · Cited by 449
Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseases
Gan, L., & Johnson, J. A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.12.011 · Cited by 288
Evidence of Oxidative Stress in the Neocortex in Incidental Lewy Body Disease
Dalfó, E., Portero-Otín, M., Ayala, V., Martínez, A., Pamplona, R., & Ferrer, I. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000179050.54522.5a · Cited by 261
The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders
Morris, G., & Berk, M. (2015) · BMC Medicine · doi:10.1186/s12916-015-0310-y · Cited by 245
The Role of Iron in Neurodegeneration: Prospects for Pharmacotherapy of Parkinson??s Disease
Jellinger, K. A. (1999) · Drugs & Aging · doi:10.2165/00002512-199914020-00004 · Cited by 218
Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson’s disease
McNaught, K. S. P., & Olanow, C. W. (2003) · Annals of Neurology · doi:10.1002/ana.10512 · Cited by 203
Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment
Andrade, S., Ramalho, M. J., Pereira, M. D. C., & Loureiro, J. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01261 · Cited by 173
Sharma, A., Weber, D., Raupbach, J., Dakal, T. C., Fließbach, K., Ramirez, A., Grune, T., & Wüllner, U. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101546 · Cited by 120
Regional NAD(P)H:quinone oxidoreductase activity in Alzheimer’s disease
SantaCruz, K. S., Yazlovitskaya, E., Collins, J., Johnson, J., & DeCarli, C. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00117-9 · Cited by 116
Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson's disease
Moreira, S., Fonseca, I., Nunes, M. J., Rosa, A., Lemos, L., Rodrigues, E., Carvalho, A. N., Outeiro, T. F., Rodrigues, C. M. P., Gama, M. J., et al. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.05.009 · Cited by 112
Morris, G., Anderson, G., Berk, M., & Maes, M. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8477-8 · Cited by 96
The PERK-Dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases
Rozpędek-Kamińska, W., Siwecka, N., Wawrzynkiewicz, A., Wojtczak, R., Pytel, D., Diehl, J. A., & Majsterek, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062108 · Cited by 84
Mitochondrial dysfunction in the striatum of aged chronic mouse model of Parkinson’s disease
Patki, G. (2009) · Frontiers in Aging Neuroscience · doi:10.3389/neuro.24.003.2009 · Cited by 20
Metadata
- Authors
- Floor, E., & Wetzel, M. G.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 1998-01
- Volume
- 70
- Issue
- 1
- Pages
- 268-275
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2021815999
- Cited by
- 452
- References
- 0
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
